<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:e sem="disease" ids="C0242647,C0334633" disease_type="Neoplastic Process" abbrv="">immunocytoma</z:e> (LLI) was defined initially as a small B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with plasmacytoid or plasmacytic features </plain></SENT>
<SENT sid="1" pm="."><plain>Because other types of small B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, particularly marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> may exhibit plasmacytic differentiation, the revised European-American <z:hpo ids='HP_0002665'>lymphoma</z:hpo> classification and World Health Organization has defined LLI more narrowly to exclude other small B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The goal of this study was to reevaluate LLI as a clinicopathologic entity </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty cases were selected from 43 previously diagnosed as "small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, plasmacytoid" or "<z:e sem="disease" ids="C0242647,C0334633" disease_type="Neoplastic Process" abbrv="">immunocytoma</z:e>" from 1985 to 1998 </plain></SENT>
<SENT sid="4" pm="."><plain>Cases fulfilling the criteria for B-cell small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, or other types of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were excluded </plain></SENT>
<SENT sid="5" pm="."><plain>The histopathology and immunoreactivity for CD20, CD79a, CD3, CD43, CD23, CD5, kappa, lambda, and immunoglobulins (Ig's) M, G, and A were reviewed, in addition to available clinical findings </plain></SENT>
<SENT sid="6" pm="."><plain>There were 13 men and seven women, with a mean age of 69 years </plain></SENT>
<SENT sid="7" pm="."><plain>Five patients had documented Waldenstr√∂m's <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">macroglobulinemia</z:e> (WM) </plain></SENT>
<SENT sid="8" pm="."><plain>Three architectural patterns were observed </plain></SENT>
<SENT sid="9" pm="."><plain>Pattern A (seven of 20) showed open sinuses, small follicles, and <z:mp ids='MP_0005639'>hemosiderosis</z:mp>; pattern B (four of 20) showed hyperplastic follicles; and pattern C (nine of 20) showed diffuse effacement </plain></SENT>
<SENT sid="10" pm="."><plain>Epithelioid histiocytes were prominent in patterns B and C but absent in A </plain></SENT>
<SENT sid="11" pm="."><plain>Cytologically, six of 20 were polymorphous with 10% to 40% transformed cells; 14 of 20 were lymphoplasmacytic </plain></SENT>
<SENT sid="12" pm="."><plain>Five cases showed minor foci of monocytoid B cells </plain></SENT>
<SENT sid="13" pm="."><plain>One case showed a composite histology of LLI and small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Amyloid was present in two cases </plain></SENT>
<SENT sid="15" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases were CD20 and/or CD79a immunoreactive, with two of 20 positive for CD43 </plain></SENT>
<SENT sid="16" pm="."><plain>Twelve cases were kappa monoclonal and eight cases were lambda monoclonal </plain></SENT>
<SENT sid="17" pm="."><plain>Twelve of 17 cases that could be evaluated were positive for IgM and five were positive for IgG </plain></SENT>
<SENT sid="18" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases were negative for CD5 and CD23 with the exception of the one case with a composite histology </plain></SENT>
<SENT sid="19" pm="."><plain>Eleven of 20 patients with available follow-up died of disease (median, 48 months), and eight of 20 are alive with disease at a follow-up of 6 months to 2 years </plain></SENT>
<SENT sid="20" pm="."><plain>LLI does appear to represent a distinct clinicopathologic entity even though it shows morphologic <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> and overlapping features with marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="21" pm="."><plain>Recognition of LLI is important because the overall prognosis may be worse than for other types of small B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>